Back to search

Italy· 028426017

MYCOBUTIN*30 cps 150 mg

A rifabutin product containing rifabutina, registered in Italy by PFIZER ITALIA Srl, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in Italy (AIFA class A)ATC J04AB04

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · ITPublic registernormalisedMYCOBUTIN*30 cps 150 mgATCJ04AB04REGISTER NO.028426017PACKS LISTED1CHECKEDJune 4, 2026

Where it is registered

Rifabutin is registered in 15 of 19 countries.

Countries holding a registration under ATC J04AB04 (rifabutin), each read from that country’s own register.

  • This record: Italy
  • 8 of them publish a price we can compare per daily dose

Rifabutin · ATC J04AB04

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rifabutin costs, country by country.

Normalised to the WHO defined daily dose (0.15 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Rifabutin · price per daily dose (0.15 g)

USD · FX 28 Sept 2026

  • CH Switzerland$5.51
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Active substance
Rifabutina
Manufacturer
PFIZER ITALIA Srl
Country
Italy (IT)
ATC code
J04AB04
ATC class
Rifabutin
Defined daily dose
0.15 g, O
Reimbursed
Yes
Last checked
June 4, 2026

Packs & prices · 1

1 priced
  • aic
    028426017
    MYCOBUTIN*30 cps 150 mg
    EUR 118.21

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

278 interactions on record for rifabutin.

Graded by severity as the source publishes them — 91 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rifabutin · interactions on record

278 records

  • 91 severe
  • 146 moderate
  • 8 minor

Most severe, free to view

  • RolapitantA04AD14severe
  • EliglustatA16AX10severe
  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe

33 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rifabutin in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rifabutin products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Austria · Mycobutin
  • Belgium · Mycobutin
  • Czechia · Mycobutin
  • Germany · Mycobutin
  • Spain · Ansatipin
  • Finland · Ansatipin
  • France · Ansatipine
  • United Kingdom (Northern Ireland) · Mycobutin, Rifabutin Pfizer
  • Ireland · Mycobutin
  • Luxembourg · Mycobutin
  • Netherlands · Mycobutin
  • Portugal · Mycobutin
  • Sweden · Ansatipin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4c3ab917-b824-4548-bd45-d286aab2acc1
GET /v1/drugs/4c3ab917-b824-4548-bd45-d286aab2acc1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "price": 118.21,
  "source": "aifa",
  "currency": "EUR",
  "strength": "RIFABUTINA 150MG 30 UNITA' USO ORALE",
  "substance": "Rifabutina",
  "equivalence_group": "R8A",
  "transparency_flag": null
}

See everything about rifabutin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.